Halozyme Therapeutics Inc. (HALO) Company Profile & Statistics

Halozyme Therapeutics Inc.
HALO
(Nasdaq - US)
Closed
53.01
+0.88 (+1.68%)
in:usd•As of: Oct 11, 2024 15:59 UTC -4
After Market:53.35+0.35 (+0.65%)
Open
52.29
High
53.14
Low
52.20

About Halozyme Therapeutics Inc.

CEO

Helen I. Torley

Headquarters

12390 el camino real

san diego, ca 92130, united states

Auditor

Ernst & Young LLP

Employees

373

Share Holders

72,264

Website

www.halozyme.com

Industry

biotechnology

Sector

health technology

Company Overview

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.

Halozyme Therapeutics Inc. Statistics

Valuation Measures

Market Capitalization ²	6.71B
Enterprise Value	8.03B
Enterprise Value/EBITDA (ttm)	16.58
Price to Earnings Ratio (ttm)	17.67
Price to Book (mrq)	23.31
Price to Sales (ttm)	7.69
Price to Cash (ytd)	16.68

Profitability

Gross Margin (ttm)	80.08%
Operating Margin (ttm)	44.85%
Profit Margin (ttm)	38.63%
Return on Equity (ttm)	195.80%
Return on Invested Capital (ttm)	19.86%
Return on Assets (ttm)	21.07%

Income Statement

Revenue (ttm)	873.30M
Revenue Per Share (ttm)	6.89
Gross Profit (ttm)	698.25M
EBITDA (ttm)³	484.34M
Net Income Avi to Common (ttm)	337.29M
Diluted EPS (ttm)	2.58

Share Statistics

Beta (5Y Monthly)	1.27
52-Week Change	45.02%
S&P500 52-Week Change	34.37%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	126.68M
Dividend Yield	0.00%
Float ⁴	123.64M
% Held by Insiders	2.40%
% Held by Institutions	97.79%

Balance Sheet

Total Cash (mrq)	529.03M
Total Cash Per Share (mrq)	4.18
Total Debt (mrq)	1.50B
Total Debt/Equity (mrq)	519.14%
Current Ratio (mrq)	7.41%
Quick Ratio (mrq)	6.21%
Book Value Per Share (mrq)	2.29

Cash Flow

Operating Cash Flow Per Share (ytd)	1.43
Free Cash Flow (ytd)	179.09M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Halozyme Therapeutics Inc.

Trade With A Regulated Broker